Skip to content

Study · Observational study · 2026

8 results

Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.

Laroche ML, Géniaux H, Jardou M

European journal of clinical pharmacology22 May 2026Cited by 1 (Europe PMC)

PMID42168638 (opens in a new tab)PMCIDPMC13194321 (opens in a new tab)DOI10.1007/s00228-026-04079-7 (opens in a new tab)PepBankPUB-42168638
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

PurposeAn increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists. We performed a pharmacovigilance data-mining analysis to characterise cases of dysesthesia related to GLP-1R.MethodsWe conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC). Additionally, we reviewed all narratives of dysesthesia cases in the French Pharmacovigilance database to extract clinical and pharmacological characteristics. A literature review complemented this analysis.ResultsExenatide was significantly associated with hypoesthesia or oral paraesthesia, semaglutide and tirzepatide with hyperaesthesia, and semaglutide with dysesthesia and burning sensation. Dysesthesia appears to be dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R, whether used for weight management or type 2 diabetes. Discontinuation was often performed, followed by spontaneous favourable outcomes, and cases of rechallenge were observed. Skin burning sensations represent a distinctive form of dysesthesia.ConclusionPharmacovigilance quantitative and qualitative data strengthens evidence for dysesthesias associated with GLP-1R agonists already observed in clinical trials of semaglutide, tirzepatide, and retatrutide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In VigiBase pharmacovigilance reports, semaglutide was significantly associated with hyperaesthesia.

    In plain wordsIn drug safety reports, semaglutide was linked to more reports of heightened skin sensitivity.

    Peptide
    Semaglutide
    Outcome
    IncreaseHyperaesthesia signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide and tirzepatide with hyperaesthesia
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).
  2. 02HumanObservational studySafety outcome

    In VigiBase pharmacovigilance reports, tirzepatide was significantly associated with hyperaesthesia.

    In plain wordsIn drug safety reports, tirzepatide was linked to more reports of heightened skin sensitivity.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHyperaesthesia signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide and tirzepatide with hyperaesthesia
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).
  3. 03HumanObservational studySafety outcome

    In VigiBase pharmacovigilance reports, semaglutide was significantly associated with dysesthesia.

    In plain wordsIn drug safety reports, semaglutide was linked to more reports of abnormal skin sensations.

    Peptide
    Semaglutide
    Outcome
    IncreaseDysesthesia signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide with dysesthesia and burning sensation.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).
  4. 04HumanObservational studySafety outcome

    In VigiBase pharmacovigilance reports, semaglutide was significantly associated with burning sensation.

    In plain wordsIn drug safety reports, semaglutide was linked to more reports of burning skin sensations.

    Peptide
    Semaglutide
    Outcome
    IncreaseBurning sensation signal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide with dysesthesia and burning sensation.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Semaglutide aloneObservational studySafety outcome

    Dysesthesia with GLP-1R agonists as a class (including semaglutide) appeared dose-dependent, more frequent at higher doses and with more potent agonists.

    In plain wordsFor GLP-1 drugs as a group, abnormal skin sensations seemed more common at higher doses and with more potent drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableDose dependence of dysesthesia with GLP-1R agonists
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    Dysesthesia appears to be dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R, whether used for weight management or type 2 diabetes.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 06HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    Dysesthesia with GLP-1R agonists as a class (including tirzepatide) appeared dose-dependent, more frequent at higher doses and with more potent agonists.

    In plain wordsFor GLP-1 drugs as a group, abnormal skin sensations seemed more common at higher doses and with more potent drugs.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDose dependence of dysesthesia with GLP-1R agonists
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    Dysesthesia appears to be dose-dependent, occurring more frequently at higher doses and with more potent GLP-1R, whether used for weight management or type 2 diabetes.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 07HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In dysesthesia cases with GLP-1R agonists as a class (including semaglutide), discontinuation was often followed by spontaneous favourable outcomes and rechallenge cases were observed.

    In plain wordsFor GLP-1 drugs as a group, stopping the drug was often followed by recovery on its own.

    Peptide
    Semaglutide
    Outcome
    Not applicableOutcome after discontinuation of GLP-1R agonists
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    Discontinuation was often performed, followed by spontaneous favourable outcomes, and cases of rechallenge were observed.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 08HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In dysesthesia cases with GLP-1R agonists as a class (including tirzepatide), discontinuation was often followed by spontaneous favourable outcomes and rechallenge cases were observed.

    In plain wordsFor GLP-1 drugs as a group, stopping the drug was often followed by recovery on its own.

    Peptide
    Tirzepatide
    Outcome
    Not applicableOutcome after discontinuation of GLP-1R agonists
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition

    Source sentences

    Summary
    Discontinuation was often performed, followed by spontaneous favourable outcomes, and cases of rechallenge were observed.
    1 context sentence
    Summary · context
    We conducted a disproportionality analysis using VigiBase data on GLP-1R (Anatomical Therapeutic Chemical classification: ATC code A10BJ) and tirzepatide, focusing on the HLT (High Level Term) "Paraesthesia and dysesthesia", with the Information Component (IC).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.